EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing

Hussain Ali iD, Carsten Buenning, David Daghfal

Diagnostics · 29.10.2025 · 15 (21) · 2744

DOI: 10.3390/diagnostics15212744 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 29.10.2025. Verfasst von Hussain Ali und 2 weiteren Autor:innen. Beteiligte Einrichtung: Abbott Diagnostics, Abbott Park, IL 60064, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatitis B virus (HBV) represents a significant global health challenge, affecting over 254 million individuals and contributing to 1.1 million deaths from liver-related complications in 2022. The World Health Organization has set ambitious targets to reduce HBV infections and mortality by 2030. However, only a small proportion (13%) of infected individuals receives timely diagnosis and treatment. HBV elimination efforts necessitate substantial improvements in HBV diagnosis, particularly in identifying early-stage infections, occult HBV infections (OBI), and breakthrough cases. The hepatitis B surface antigen (HBsAg) is a key biomarker in HBV diagnosis, serving as a reliable indicator of infection status and treatment response. Conventional HBsAg assays, with a lower limit of detection (LoD) between 0.03 and 250 IU/mL, often fail to detect OBI and HBV reactivation. In contrast, ultrasensitive HBsAg assays, with an LoD as low as 0.005 IU/mL, can improve the identification of low concentration levels of HBsAg, facilitating earlier diagnosis, monitoring of therapeutic response, and assessment for functional cure. Research confirms the superiority of ultrasensitive assays in detecting HBV in cases missed by conventional assays, detecting NAT-yield samples, and enabling earlier detection of HBV reactivation. This review examines the challenges in HBV diagnostics and the clinical utility of ultrasensitive HBsAg assays in improving progress toward global HBV elimination.

Schlagwörter

Stichwörter der Autor:innen

HBV diagnosticsHBV eliminationchronic hepatitis infectiondiagnostic sensitivityearly detectionfunctional curehepatitis B viruslower limit of detectiontherapeutic monitoring

Autor:innen und Institutionen

  • Abbott Diagnostics, Abbott Park, IL 60064, USA.

ORCID-Profile: Hussain Ali

Zitieren

APA

Ali, H., Buenning, C., & Daghfal, D. (2025). Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing. Diagnostics, 15(21), 2744. https://doi.org/10.3390/diagnostics15212744

Vancouver

Ali H, Buenning C, Daghfal D. Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing. Diagnostics. 2025;15(21):2744. doi:10.3390/diagnostics15212744

BibTeX
@article{Ali2025,
  author = {Ali, Hussain and Buenning, Carsten and Daghfal, David},
  title = {Advancing HBV Diagnostics: The Role of Ultrasensitive HBsAg Testing},
  journal = {Diagnostics},
  year = {2025},
  volume = {15},
  number = {21},
  pages = {2744},
  doi = {10.3390/diagnostics15212744}
}
Kostenlos starten →